1
|
Mansour Y, Boubaddi M, Odion T, Marty M, Belleannée G, Berger A, Subtil C, Laurent C, Dabernat S, Amintas S. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation. Cancer Cytopathol 2024. [PMID: 38308613 DOI: 10.1002/cncy.22795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 12/20/2023] [Accepted: 12/20/2023] [Indexed: 02/05/2024]
Abstract
BACKGROUND Pancreatic adenocarcinoma (PDAC) is associated with a 5-year survival rate of less than 6%, and current treatments have limited efficacy. The diagnosis of PDAC is mainly based on a cytologic analysis of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) samples. However, the collected specimens may prove noncontributory in a significant number of cases, delaying patient management and treatment. The combination of EUS-FNA sample examination and KRAS mutation detection can improve the sensitivity for diagnosis. In this context, the material used for molecular analysis may condition performance. METHODS The authors prospectively compared the performance of cytologic analysis combined with a KRAS droplet digital polymerase chain reaction (ddPCR) assay for PDAC diagnosis using either conventional formalin-fixed, paraffin-embedded cytologic samples or needle-rinsing fluids. RESULTS Molecular testing of formalin-fixed, paraffin-embedded cytologic samples was easier to set up, but the authors observed that the treatment of preanalytic samples, in particular the fixation process, drastically reduced ddPCR sensitivity, increasing the risk of false-negative results. Conversely, the analysis of dedicated, fresh needle-rinsing fluid samples appeared to be ideal for ddPCR analysis; it had greater sensitivity and was easily to implement in clinical use. In particular, fluid collection by the endoscopist, transportation to the laboratory, and subsequent freezing did not affect DNA quantity or quality. Moreover, the addition of KRAS mutation detection to cytologic examination improved diagnosis performance, regardless of the source of the sample. CONCLUSIONS Considering all of these aspects, the authors propose the use of an integrated flowchart for the KRAS molecular testing of EUS-FNA samples in clinical routine.
Collapse
Affiliation(s)
- Yara Mansour
- Pathology Department, Bordeaux University Hospital Center (CHU Bordeaux), Bordeaux, France
| | - Mehdi Boubaddi
- Digestive Surgery Department, CHU Bordeaux, Pessac, France
- Bordeaux Institute of Oncology, UMR Unit 1312, INSERM, University of Bordeaux, Bordeaux, France
| | - Typhaine Odion
- Pathology Department, Bordeaux University Hospital Center (CHU Bordeaux), Bordeaux, France
| | - Marion Marty
- Pathology Department, Bordeaux University Hospital Center (CHU Bordeaux), Bordeaux, France
| | - Geneviève Belleannée
- Pathology Department, Bordeaux University Hospital Center (CHU Bordeaux), Bordeaux, France
| | - Arthur Berger
- Gastroenterology and Hepatology Department, CHU Bordeaux, Pessac, France
| | - Clément Subtil
- Gastroenterology and Hepatology Department, CHU Bordeaux, Pessac, France
| | - Christophe Laurent
- Digestive Surgery Department, CHU Bordeaux, Pessac, France
- Bordeaux Institute of Oncology, UMR Unit 1312, INSERM, University of Bordeaux, Bordeaux, France
| | - Sandrine Dabernat
- Bordeaux Institute of Oncology, UMR Unit 1312, INSERM, University of Bordeaux, Bordeaux, France
- Biochemistry Laboratory, CHU Bordeaux, Pessac, France
| | - Samuel Amintas
- Bordeaux Institute of Oncology, UMR Unit 1312, INSERM, University of Bordeaux, Bordeaux, France
- Tumor Biology and Tumor Bank Laboratory, CHU Bordeaux, Pessac, France
| |
Collapse
|
2
|
Boubaddi M, Teixeira Farinha H, Lambert C, Pereira B, Piessen G, Gualtierotti M, Voron T, Mantziari S, Pezet D, Gronnier C. ASO Visual Abstract: Total Versus Subtotal Gastrectomy for Distal Gastric Poorly Cohesive Carcinoma. Ann Surg Oncol 2024; 31:814-815. [PMID: 37978106 DOI: 10.1245/s10434-023-14571-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Affiliation(s)
- Mehdi Boubaddi
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France
| | - Hugo Teixeira Farinha
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France
- Department of Visceral Surgery, University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | - Céline Lambert
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
- Department of Digestive Surgery, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Bruno Pereira
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
- Department of Digestive Surgery, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Guillaume Piessen
- Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France
| | - Monica Gualtierotti
- Division of Minimally Invasive Surgical Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Thibault Voron
- Department of General and Digestive Surgery, Saint-Antoine Hospital, Paris, France
| | - Styliani Mantziari
- Department of Visceral Surgery, University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | - Denis Pezet
- Bordeaux University Hospital, U1312 Bordeaux Institute of Oncology, INSERM, Bordeaux, France
| | - Caroline Gronnier
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France.
- Bordeaux University Hospital, U1312 Bordeaux Institute of Oncology, INSERM, Bordeaux, France.
| |
Collapse
|
3
|
Boubaddi M, Teixeira Farinha H, Lambert C, Pereira B, Piessen G, Gualtierotti M, Voron T, Mantziari S, Pezet D, Gronnier C. Total Versus Subtotal Gastrectomy for Distal Gastric Poorly Cohesive Carcinoma. Ann Surg Oncol 2024; 31:744-752. [PMID: 37971616 DOI: 10.1245/s10434-023-14496-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 10/10/2023] [Indexed: 11/19/2023]
Abstract
BACKGROUND Gastric poorly cohesive carcinoma (PCC) in advanced stages has a poor prognosis. Total gastrectomy (TG) remains the common treatment for distal gastric PCC, but subtotal gastrectomy (SG) may improve quality of life without compromising outcomes. Currently, no clear recommendation on the best surgical strategy for distal PCC is available. This study aimed to compare overall survival (OS) and disease-free survival (DFS) at 5 years for patients with antropyloric PCC treated by total versus subtotal gastrectomy. METHODS A large retrospective European multicenter cohort study analyzed 2131 patients treated for gastric cancer between 2007 and 2017 by members of the French Association of Surgery (AFC). The study compared a group of patients who underwent TG with a group who underwent SG for antropyloric PCC. The primary outcomes were 5 year OS and DFS. RESULTS The study enrolled 269 patients: 140 (52.0%) in the TG group and 129 (48.0%) in the SG group. The baseline characteristics and pTNM stage were similar between the two groups. According to Dindo-Claven classification, the patients treated with TG had more postoperative complications than the patients treated with SG (p < 0.001): grades I to IIIa (77.1% vs 59.5%) and grades IIIb to IVb (14.4% vs 9.0%). No difference in 5-year OS was observed between TG (53.8%; 95 % confidence interval [CI], 43.2-63.3%) and SG (53.0%; 95% CI, 41.4-63.3%) (hazard ratio [HR], 0.94; 95% CI, 0.68-1.29). The same was observed for 5-year DFS: TG (46.0%; 95% CI, 35.9-55.5%) versus SG (45.3%; 95% CI, 34.3-55.6%) (HR, 0.97; 95% CI, 0.70-1.34). CONCLUSIONS At 5 years, SG was not associated with worse OS and DFS than TG for distal PCC. Surgical morbidity was higher after TG. Subtotal gastrectomy is a valuable option for distal PCC gastric cancer.
Collapse
Affiliation(s)
- Mehdi Boubaddi
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France
| | - Hugo Teixeira Farinha
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France
- Department of Visceral Surgery, University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | - Céline Lambert
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
- Department of Digestive Surgery, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Bruno Pereira
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
- Department of Digestive Surgery, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Guillaume Piessen
- Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France
| | - Monica Gualtierotti
- Division of Minimally Invasive Surgical Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Thibault Voron
- Department of General and Digestive Surgery, Saint-Antoine Hospital, Paris, France
| | - Styliani Mantziari
- Department of Visceral Surgery, University Hospital of Lausanne, CHUV, Lausanne, Switzerland
| | - Denis Pezet
- Bordeaux University Hospital, U1312 Bordeaux Institute of Oncology, INSERM, Bordeaux, France
| | - Caroline Gronnier
- Oeso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Bordeaux, France.
- Bordeaux University Hospital, U1312 Bordeaux Institute of Oncology, INSERM, Bordeaux, France.
| |
Collapse
|
4
|
Boubaddi M, Marichez A, Adam JP, Chiche L, Laurent C. Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma. Eur J Surg Oncol 2024; 50:107960. [PMID: 38219701 DOI: 10.1016/j.ejso.2024.107960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/12/2023] [Accepted: 01/09/2024] [Indexed: 01/16/2024]
Abstract
BACKGROUND Clear-cell renal cell carcinoma frequently metastasizes to the pancreas (PMRCC). The management of such metastases remains controversial due to their frequent multifocality and indolent evolution. METHODS This study describes the surgical management of these lesions and their long-term oncological outcomes. The study included patients who underwent pancreatic resection of PMRCC at Bordeaux University Hospital between June 2005 and March 2022. Morbidity and mortality were assessed at 90 days. Overall survival (OS) and disease-free (DFS) survival were assessed at 5 years. RESULTS Forty-two patients underwent pancreatic resection for PMRCC, including 18 (42.8 %) total pancreatectomies. The median time from nephrectomy to the diagnosis of PMRCC was 121 (range: 6-400) months. Lesions were multiple in 19/42 (45.2 %) patients. Ten (23.8 %) patients suffered a severe complication (Dindo-Clavien classification ≥ IIIA by D90), including one patient who died postoperatively. The median follow-up was 76 months. The R0 rate was 100 %. The OS and DFS rates were 92.8 % and 29.6 %, respectively, at 5 years. CONCLUSION Pancreatic resection for PMRCC provides long-term oncological control despite a high recurrence rate.
Collapse
Affiliation(s)
- Mehdi Boubaddi
- Department of Digestive Surgery, Hepatobiliary and Pancreatic Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France.
| | - Arthur Marichez
- Department of Digestive Surgery, Hepatobiliary and Pancreatic Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France
| | - Jean Philippe Adam
- Department of Digestive Surgery, Hepatobiliary and Pancreatic Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France
| | - Laurence Chiche
- Department of Digestive Surgery, Hepatobiliary and Pancreatic Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France
| | - Christophe Laurent
- Department of Digestive Surgery, Hepatobiliary and Pancreatic Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France
| |
Collapse
|
5
|
Boubaddi M, Fleming C, Vendrely V, Frulio N, Salut C, Rullier E, Denost Q. Feasibility study of a Response Surveillance Program in locally advanced mid and low rectal cancer to increase organ preservation. Eur J Surg Oncol 2023; 49:237-243. [PMID: 36114048 DOI: 10.1016/j.ejso.2022.08.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 08/02/2022] [Accepted: 08/25/2022] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Assessment of tumor response in rectal cancer after neoadjuvant treatment by MRI (Tumour Regression Grade, TRG 1-5) is well standardized. The overall timing and method of defining complete response (cCR) remain controversial. The aim of this work was to evaluate the feasibility of a defined Response Surveillance Program (RSP) to increase organ preservation for locally advanced rectal cancer after neoadjuvant treatment. METHODS A standardized program of clinical (CR), radiological (RR) and metabolic (MR) assessment of tumor response is defined over a 6 month period from completion of NACRT with formal assessment performed every 2 months (M). Patients with TRG1-3 at M2 and TRG1-2 at M4 continue in the program up to M6 assessment. Patients managed with this protocol from 2016 to 2020 were analyzed. The primary endpoint was rectal preservation rate. Secondary endpoints included disease-free survival and overall survival at 3 years. RESULT 314 potentially suitable patients were enrolled in the RSP and 50 patients completed the six month program and were successfully enrolled into watch and wait. Fourteen (28%) were T2 tumor stage, 27 (54%) T3 and nine (18%) were T4. During watch and wait, patients with locoregional recurrence (n = 11) were treated with local excision (n = 3), endocavitary radiotherapy (n = 1), TME (n = 5) and APR (n = 2). With a median follow-up of 32 months, the rectal preservation rate was 88%, with a 3-year disease-free survival of 67% and an overall survival of 98%. CONCLUSION This study validates the feasibility of the practical implementation of a Response Surveillance Program to increase organ preservation rates without compromising oncological outcomes in rectal cancer.
Collapse
Affiliation(s)
| | | | | | - Nora Frulio
- Department of Radiology, CHU, Bordeaux, France
| | | | - Eric Rullier
- Department of Colorectal Surgery, CHU, Bordeaux, France
| | - Quentin Denost
- Department of Colorectal Surgery, CHU, Bordeaux, France.
| |
Collapse
|
6
|
Bouriez D, Belaroussi Y, Boubaddi M, Martre P, Najah H, Berger P, Gronnier C, Collet D. Laparoscopic fundoplication for para-oesophageal hernia repair improves respiratory function in patients with dyspnoea: a prospective cohort study. Surg Endosc 2022; 36:7266-7278. [PMID: 35732837 PMCID: PMC9216289 DOI: 10.1007/s00464-022-09127-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Accepted: 02/07/2022] [Indexed: 01/20/2023]
Abstract
Background Dyspnoea in patients with a para-oesophageal hernia (PEH) occurs in 7% to 32% of cases and is very disabling, especially in elderly patients, and its origin is not well defined. The present study aims to assess the impact of PEH repair on dyspnoea and respiratory function. Methods From January 2019 to May 2021, all consecutive patients scheduled for PEH repair presenting with a modified Medical Research Council (mMRC) score ≥ 2 for dyspnoea were included. Before and 2 months after surgery, dyspnoea was assessed by both the dyspnoea visual analogue scale (DVAS) and the mMRC scale, as well as pulmonary function tests (PFTs) by plethysmography. Results All 43 patients that were included had pre- and postoperative dyspnoea assessments and PFTs. Median age was 70 years (range 63–73.5 years), 37 (86%) participants were women, median percentage of the intrathoracic stomach was 59.9% (range 44.2–83.0%), and median length of hospital stay was 3 days (range 3–4 days). After surgery, the DVAS decreased statistically significant (5.6 [4.7–6.7] vs. 3.0 [2.3–4.4], p < 0.001), and 37 (86%) patients had a clinically significant decrease in mMRC score. Absolute forced expiratory volume in one second (FEV1), total lung capacity, and forced vital capacity also statistically significantly increased after surgery by an average of 11.2% (SD 17.9), 5.0% (SD 13.9), and 10.7% (SD 14.6), respectively. Furthermore, from the subgroup analysis, it was identified that patients with a lower preoperative FEV1 were more likely to have improvement in it after surgery. No correlation was found between improvement in dyspnoea and FEV1. There was no correlation between the percentage of intrathoracic stomach and dyspnoea or improvement in PFT parameters. Conclusion PEH repair improves dyspnoea and FEV1 in a statistically significant manner in a population of patients presenting with dyspnoea. Patients with a low preoperative FEV1 are more likely to have improvement in it after surgery.
Collapse
Affiliation(s)
- Damien Bouriez
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
| | - Yaniss Belaroussi
- Thoracic Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
- INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, 33076, Bordeaux, France
| | - Mehdi Boubaddi
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
| | - Paul Martre
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
| | - Haythem Najah
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
| | - Patrick Berger
- Pulmonary Function Tests Department, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
- University of Bordeaux, Bordeaux, France
| | - Caroline Gronnier
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France.
- University of Bordeaux, Bordeaux, France.
- INSERM, U1053, Bordeaux, France.
| | - Denis Collet
- Esophagogastric Surgery Unit, Haut Lévêque Hospital, CHU Bordeaux, Bordeaux, France
- University of Bordeaux, Bordeaux, France
| |
Collapse
|